Perceptive Advisors’s Capricor Therapeutics CAPR Stock Holding History

Perceptive Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-400	Closed	-$4K	–	105
2018 Q3	$4K	Hold	400	–	–	﹤0.01%	117
2018 Q2	$5K	Hold	400	–	–	﹤0.01%	125
2018 Q1	$5K	Hold	400	–	–	﹤0.01%	137
2017 Q4	$6K	Buy	+400	New	+$8.66K	﹤0.01%	132
2017 Q2	–	Sell	-400	Closed	-$13K	–	140
2017 Q1	$13K	Hold	400	–	–	﹤0.01%	148
2016 Q4	$11K	Hold	400	–	–	﹤0.01%	162
2016 Q3	$13K	Hold	400	–	–	﹤0.01%	182
2016 Q2	$16K	Hold	400	–	–	﹤0.01%	164
2016 Q1	$10K	Hold	400	–	–	﹤0.01%	165
2015 Q4	$12K	Hold	400	–	–	﹤0.01%	153
2015 Q3	$16K	Hold	400	–	–	﹤0.01%	154
2015 Q2	$20K	Hold	400	–	–	﹤0.01%	172
2015 Q1	$35K	Buy	+400	New	+$34.5K	﹤0.01%	153

Other funds holding CAPR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JHC

Jones Hill Capital New York $466M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors's CAPR Position: Q4 2018 in Review

Perceptive Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2018, closing a stake of 400 shares — an estimated $4K sold.

Perceptive Advisors first reported a position in CAPR in Q1 2015 and held it in 13 quarters. The position peaked at $35K in Q1 2015. 18 funds tracked by Wall St. Rank hold CAPR as of Q4 2018.

Perceptive Advisors reported no remaining Capricor Therapeutics position as of Q4 2018 after selling out during the quarter.
Perceptive Advisors sold 400 Capricor Therapeutics shares in Q4 2018, an estimated $4K.
Perceptive Advisors first reported a position in Capricor Therapeutics in Q1 2015 and held it in 13 quarters.
Perceptive Advisors's Capricor Therapeutics position peaked at $35K in Q1 2015.
18 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.